Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shanghai - Delayed Quote CNY

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd (600721.SS)

6.63
-0.04
(-0.60%)
At close: April 30 at 3:00:04 PM GMT+8
Loading Chart for 600721.SS
  • Previous Close 6.67
  • Open 6.76
  • Bid 6.62 x --
  • Ask 6.63 x --
  • Day's Range 6.62 - 6.76
  • 52 Week Range 5.07 - 8.67
  • Volume 14,803,900
  • Avg. Volume 26,811,370
  • Market Cap (intraday) 2.547B
  • Beta (5Y Monthly) 0.15
  • PE Ratio (TTM) 60.27
  • EPS (TTM) 0.11
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date May 22, 1997
  • 1y Target Est --

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd engages in the pharmaceutical research and development, clinical trials, biomedicine, commercial properties, and other businesses. The company was formerly known as Xinjiang Baihuacun Co., Ltd. and changed its name to Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd in July 2021. Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd was founded in 1959 and is based in Urumqi, China.

www.xjbhc.net

731

Full Time Employees

December 31

Fiscal Year Ends

Restaurants

Industry

Recent News: 600721.SS

View More

Performance Overview: 600721.SS

Trailing total returns as of 4/30/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

600721.SS
0.61%
SSE Composite Index (000001.SS)
2.17%

1-Year Return

600721.SS
9.59%
SSE Composite Index (000001.SS)
5.61%

3-Year Return

600721.SS
11.95%
SSE Composite Index (000001.SS)
7.61%

5-Year Return

600721.SS
23.01%
SSE Composite Index (000001.SS)
14.65%

Compare To: 600721.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 600721.SS

View More

Valuation Measures

Annual
As of 4/30/2025
  • Market Cap

    2.55B

  • Enterprise Value

    2.30B

  • Trailing P/E

    61.16

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.48

  • Price/Book (mrq)

    3.27

  • Enterprise Value/Revenue

    5.87

  • Enterprise Value/EBITDA

    23.60

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.75%

  • Return on Assets (ttm)

    1.76%

  • Return on Equity (ttm)

    5.66%

  • Revenue (ttm)

    385.76M

  • Net Income Avi to Common (ttm)

    41.48M

  • Diluted EPS (ttm)

    0.11

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    272.05M

  • Total Debt/Equity (mrq)

    0.01%

  • Levered Free Cash Flow (ttm)

    66.32M

Research Analysis: 600721.SS

View More

Company Insights: 600721.SS

Research Reports: 600721.SS

View More

People Also Watch